Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Antifibrotic Therapy
Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial
Posted innews Oncology Radiology Respiratory

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial

Posted by MedXY By MedXY 11/12/2025
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
Read More
Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
Posted inClinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

Posted by MedXY By MedXY 09/17/2025
The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.
Read More
  • The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures
  • Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
  • Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
  • B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia
  • Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in